Cancer patients are at high risk
of potentially fatal blood clots
that form in the large veins in the leg (venous thromboembolism) that, if
unrecognized or untreated, can lead to a potentially fatal pulmonary embolism.
In fact, as many as 1 in 7 hospitalized cancer patients die of a fatal
thromboembolic event rather than their cancer.
A recently launched international initiativeFundamental
Research in ONcology and Thrombosis (FRONTLINE)will be the first global
survey to collect information from physicians treating cancer patients with the
goal of establishing the risk of venous thrombosis, documenting the prevention
and treatment strategies currently employed, and seeking national treatment
Cancer specialists across Europe, North and South America and
the Asia-Pacific region are expected to participate in FRONTLINE, and intensive
efforts will be made to collect data from as large and representative a sample
as possible. Importantly, participation will be encouraged from all types of
medical centers, not only those that regularly take part in clinical trials. The
results will help to build a picture of what is happening in routine clinical
The FRONTLINE Survey will collect information on:
The types of cancer patients who develop venous
thromboembolism, and with which cancer treatments
Strategies physicians use for prophylaxis, its diagnosis
Factors that may influence treatment decisions.
It is hoped that the FRONTLINE Survey may pave the way for an
international registry of cases of cancer-associated thromboembolic disease.
Current Perceptions and Practice
Venous thrombosis is an important cause of morbidity and
mortality in cancer patients, and yet the clinical impact is often
underestimated. Little is known about prevention strategies, diagnosis, and
treatment in routine clinical practice. FRONTLINE is designed to help
researchers understand current practice patterns and key issues surrounding this
important clinical problem. It is hoped that as many clinicians treating cancer
as possible will contribute, thus helping to provide much new information on
current perceptions and practice.
Led by a distinguished scientific steering committee chaired by
Dr. Ajay Kakkar, of Hammersmith Hospital, Imperial College, London, the
FRONTLINE Survey is supported by an unrestricted educational grant from the
Pharmacia Corporation. For more information about FRONTLINE, visit www.frontlinesurvey.net, or contact: